Grid AI Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
GRDX
- Investments
-
4
- Share Price
-
$3.17
- (As of Friday Closing)
Grid AI General Information
Description
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Contact Information
Website
www.grid-ai.comCorporate Office
- 91 George Street
- Edinburgh
- Scotland, United Kingdom
Corporate Office
- 91 George Street
- Edinburgh
- Scotland, United Kingdom
Grid AI Timeline
Grid AI Stock Performance
As of 20-Nov-2026, Grid AI’s stock price is $3.17. Its current market cap is $32.4M with 10.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.17 | $3.45 | $1.87 - $6.93 | $32.4M | 10.3M | 122K | -$4.24 |
Grid AI Financials Summary
As of 30-Sep-2026, Grid AI has a trailing 12-month revenue of $198K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 35,472 | 81,189 | 64,431 | (226) |
| Revenue | 198 | 36 | 0 | 0 |
| EBITDA | (20,744) | (5,574) | (15,571) | (15,746) |
| Net Income | (22,165) | (6,393) | (18,059) | (15,795) |
| Total Assets | 38,057 | 48,552 | 85,410 | 6,883 |
| Total Debt | 1,979 | 2,264 | 141 | 827 |
Grid AI Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Grid AI Comparisons
Industry
Financing
Details
Grid AI Competitors (5)
One of Grid AI’s 5 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
| MetaVia (Biotechnology) | Formerly VC-backed | Cambridge, MA | ||||
| Alcresta Therapeutics | Private Equity-Backed | Waltham, MA | ||||
| Union Therapeutics | Venture Capital-Backed | Hellerup, Denmark | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA |
Grid AI Patents
Grid AI Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024119044-A2 | Adrulipase compositions | Inactive | 01-Dec-2022 | ||
| WO-2024119044-A3 | Adrulipase compositions | Inactive | 01-Dec-2022 | ||
| WO-2023163883-A1 | Compositions and methods for treating pouchitis | Inactive | 22-Feb-2022 | ||
| CA-3241068-A1 | Lipase formulations and methods thereof | Pending | 16-Dec-2021 | ||
| EP-4448741-A2 | Lipase formulations and methods thereof | Inactive | 16-Dec-2021 | C12N9/20 |
Grid AI Signals
Grid AI Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Grid AI Acquisitions (4)
Grid AI’s most recent deal was a Merger/Acquisition with Pronghorn Resources. The deal was made on 13-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pronghorn Resources | 13-Nov-2026 | Merger/Acquisition | Energy Production | ||
| Grid AI(Business/Productivity Software) | 30-Sep-2025 | Merger/Acquisition | Business/Productivity Software | ||
| ImmunogenX | 13-Mar-2024 | Merger/Acquisition | Drug Discovery | ||
| AzurRx BioPharma | 22-Sep-2021 | Merger/Acquisition | Drug Discovery |
Grid AI ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Grid AI Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Grid AI(Business/Productivity Software) | Edinburgh, United Kingdom | 2022 | |
| First Wave BioPharma (Niclosamide Program) | Boca Raton, FL |
Grid AI FAQs
-
When was Grid AI founded?
Grid AI was founded in 2014.
-
Where is Grid AI headquartered?
Grid AI is headquartered in Edinburgh, United Kingdom.
-
What is the size of Grid AI?
Grid AI has 2 total employees.
-
What industry is Grid AI in?
Grid AI’s primary industry is Business/Productivity Software.
-
Is Grid AI a private or public company?
Grid AI is a Public company.
-
What is Grid AI’s stock symbol?
The ticker symbol for Grid AI is GRDX.
-
What is the current stock price of Grid AI?
As of 20-Nov-2026 the stock price of Grid AI is $3.17.
-
What is the current market cap of Grid AI?
The current market capitalization of Grid AI is $32.4M.
-
What is Grid AI’s current revenue?
The trailing twelve month revenue for Grid AI is $198K.
-
Who are Grid AI’s competitors?
Phathom Pharmaceuticals, MetaVia (Biotechnology), Alcresta Therapeutics, Union Therapeutics, and Vedanta Biosciences are competitors of Grid AI.
-
What is Grid AI’s annual earnings per share (EPS)?
Grid AI’s EPS for 12 months was -$4.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process